Search clinical trials for: intermediate risk

Total 16036 results

Jesper Kjaergaard
Zealand University Hospital; Copenhagen University Hospital at Herlev

Active, not recruiting

Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY-II)

Pulmonary Embolism

Denmark
Albert Einstein College of Medicine

Active, not recruiting

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (PROSINT)

Prostate Cancer

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Oral Cancer | Larynx | Lip | Digestive Organs--Diseases

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
M.D. Anderson Cancer Center

Suspended

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
University of Chicago

Active, not recruiting

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
University of Chicago
Janssen, LP

Suspended

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
University of Leipzig
Curis, Inc.

Terminated

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
University of Birmingham
AstraZeneca; Cancer Trials Ireland

Active, not recruiting

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

Oropharyngeal Cancer

United Kingdom, Ireland
Moscow City Oncology Hospital No. 62

Completed

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer (SENTRY)

Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Endometrial Endometrioid Adenocarcinoma | Endometrial Adenocarcinoma | Hysterectomy | Endometrial Cancer Stage I | Laparoscopic Hysterectomy | Endometrial Cancer Stage II

Russian Federation
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Medtronic Cardiovascular

Active, not recruiting

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). (SURTAVI)

Severe Aortic Stenosis

United States, Netherlands, Canada, Spain, Denmark, United Kingdom, Switzerland, Germany, Sweden
Universitätsklinikum Hamburg-Eppendorf
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK); Deutsche Herzstiftung...

Active, not recruiting

Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality (DEDICATE)

Aortic Valve Stenosis

Germany
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
St. Jude Children's Research Hospital
National Cancer Institute (NCI); University of Florida; The Pew Charitable Trusts

Active, not recruiting

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Brain and Central Nervous System Tumors

United States, Australia
NYU Langone Health
Perlmutter Cancer Center

Completed

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Myelodysplastic Syndromes

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
UNC Lineberger Comprehensive Cancer Center

Withdrawn

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Edwards Lifesciences

Completed

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk (PII A)

Symptomatic Severe Aortic Stenosis

United States, Canada
Memorial Sloan Kettering Cancer Center

Completed

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Prostate Cancer

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Prostate Cancer | Prostatic Adenocarcinoma

United States
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Hospices Civils de Lyon

Active, not recruiting

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer (FOCALE)

Prostate Cancer

France, Sweden
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

Myelodysplastic Syndromes

Germany
CSSS de Gatineau

Active, not recruiting

Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

Prostate Cancer

Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
Ashok Muthukrishnan
Progenics Pharmaceuticals, Inc.

Terminated

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Azienda U.S.L. 1 di Massa e Carrara

Withdrawn

Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism (MONALYSE)

Pulmonary Embolism
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Leukemia

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Royal Marsden NHS Foundation Trust
The Institute of Cancer Research, Sutton, Surrey, UK

Active, not recruiting

Prostate Advances in Comparative Evidence (PACE)

Prostate Cancer

New Zealand, Ireland, United Kingdom, Canada
Baylor College of Medicine

Completed

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (TXCH-HD-12A)

Hodgkin Disease

United States
Celgene

Completed

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (RevlimidPMS)

Lymphoma, Follicular | Myelodysplastic Syndromes | Lymphoma, Mantle-Cell

Korea, Republic of
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Oropharyngeal Squamous Cell Carcinoma

Canada, Spain, Belgium, Italy
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Active, not recruiting

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Oropharynx Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States

Search clinical trials for: intermediate risk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations